Market Cap 3.80B
Revenue (ttm) 806.78M
Net Income (ttm) -363.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -45.03%
Debt to Equity Ratio -2.16
Volume 674,700
Avg Vol 974,162
Day's Range N/A - N/A
Shares Out 78.87M
Stochastic %K 95%
Beta 0.58
Analysts Sell
Price Target $63.80

Latest News on PTCT

Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 23 days ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PCVX XBI


PTC Therapeutics: Upside In Rare Disease Innovation

Mar 9, 2025, 9:47 AM EDT - 6 weeks ago

PTC Therapeutics: Upside In Rare Disease Innovation


PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:41 PM EST - 7 weeks ago

PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript


PTC Therapeutics to Participate in Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 2 months ago

PTC Therapeutics to Participate in Upcoming Investor Conferences


PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Dec 2, 2024, 1:50 PM EST - 5 months ago

PTC Therapeutics Stock Soars on Novartis Licensing Agreement


PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 11:19 PM EST - 5 months ago

PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript


CHMP Maintains Negative Opinion on Translarna™ Reexamination

Oct 18, 2024, 6:30 AM EDT - 6 months ago

CHMP Maintains Negative Opinion on Translarna™ Reexamination


PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 11:53 AM EDT - 9 months ago

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript


PTC Therapeutics Announces Sepiapterin NDA Submission to FDA

Jul 30, 2024, 8:00 AM EDT - 9 months ago

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA